Showing 8281-8290 of 8821 results for "".
- Aclaris Therapeutics' A-101 Achieves Positive Results in Clinical Trial for Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-a-101-achieves-positive-results-in-clinical-trial-for-seborrheic-keratosis/2458989/Aclaris Therapeutics, Inc.’s lead drug candidate A-10 demonstrated clinically and statistically significant improvements in removing seborrheic keratosis (SK) lesions on the face in its third Phase II clinical trial. The double-blind, vehicle-controlled Phase 2 clinical trial was designed t
- Envy Medical Unveils SilkPeel3https://practicaldermatology.com/news/envy-medical-unveils-silkpeel3/2458990/Envy Medical, Inc. will launch its SilkPeel3, the next generation of its Advanced Dermalinfusion Technology, at the Annual Meeting of the American Academy of Dermatology on March 20-24 in San Francisco at Booth 312. Unveiled originally in 2005, SilkPeel is celebrating its 10th
- Practical Dermatology® and NewDerm MD Announce Social Media Contesthttps://practicaldermatology.com/news/practical-dermatology-and-newderm-md-announce-social-media-contest/2458994/Follow NewDermMD on Twitter (@NewDermMD) and download the NewDermMD app and complete a brief survey between March 18 to April 17 for your chance to win a FujiFilm XQ2 Digital Camera with wi-fi for your practice. Dedicated to future lead
- National Psoriasis Foundation's Patient Registry Begins Recruitinghttps://practicaldermatology.com/news/national-psoriasis-foundations-patient-registry-begins-recruiting/2458999/People with psoriasis and their health care providers will have the opportunity to participate in re
- Envy Medical Appoints Chief Marketing Officer to Executive Teamhttps://practicaldermatology.com/news/envy-medical-appoints-chief-marketing-officer-to-executive-team/2459002/Envy Medical Products, Inc., appointed Shauna Lahiri to the newly created role of Chief Marketing Officer. Ms. Lahiri brings a 17-year record of building successful global marketing strategies, building and launching new brands achieving leadership in mas
- Can-Fite Receives Notice of Allowance in US for Psoriasis Patenthttps://practicaldermatology.com/news/can-fite-receives-notice-of-allowance-in-us-for-psoriasis-patent/2459005/Can-Fite BioPharma Ltd. received a Notice of Allowance from the US Patent and Trademark Office for CF101 in the treatment of psoriasis. The patent, which is expected to be issued in the next few weeks, is titled, "Pharmaceutical Composition Comprising A3 Adenosine Receptor Agonist (IB-M
- Syneron Medical Appoints William Griffing to Newly Created Position of CEO of Syneron Candela North Americahttps://practicaldermatology.com/news/syneron-medical-appoints-william-griffing-to-newly-created-position-of-ceo-of-syneron-candela-north-america/2459009/Syneron Medical Ltd. appointed William Griffing to the newly created position of Chief Executive Officer of Syneron Candela North America, effective immediately. In this position, Mr. Griffing will be responsible for aligning and managing the Company's growth strategies for its North American
- Mikael Svensson Named Sr. VP of Sales/Marketing for Revision Skincarehttps://practicaldermatology.com/news/mikael-svensson-named-sr-vp-of-salesmarketing-for-revision-skincare/2459010/Revision Skincare appointed Mikael Svensson to the position of Senior Vice President of Sales and Marketing. In this new role, Mr. Svensson will oversee all Sales and Marketing activities, which include the strategic direction and leadership of Revis
- Aclaris Therapeutics Announces Positive Results from Phase IIb Trial of A-101 for the Removal of Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-announces-positive-results-from-phase-iib-trial-of-a-101-for-the-removal-of-seborrheic-keratosis/2459016/Aclaris Therapeutics, Inc. announced positive results from a Phase IIb clinical trial of the Company’s lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing multiple seborrheic keratoses (SK). Though the lesions are benign, many
- Alphaeon Begins Phase III Study For Its Neurotoxin, Evosyalhttps://practicaldermatology.com/news/alphaeon-begins-phase-iii-study-for-its-neurotoxin-evosyal/2459018/The FDA agreed to Alphaeon® Corporations’s protocol for its Phase III clinical study of Evosyal™ to treat glabellar lines. Alphaeon acquired the exclusive US and certain international distribution rights to Evosyal, a botulinum toxin type A neuromodulator, as part of it